Catalent and CTC Partner to Help Korean Pharma Take Their Products to Western Markets
October 2, 2012Research and Development
Somerset, NJ, September 13, 2012 – Catalent Pharma Solutions and CTC Bio have entered into a collaboration to provide optimal …
Catalent Enters Into Commerical Supply Agreement with Vivus for Qsymia™ Once-Daily Combination Extended-Release Capsules
October 2, 2012Manufacturing and Production
Somerset, NJ, October 1, 2012 – Catalent Pharma Solutions announced that it has entered into a Supply Agreement with VIVUS, …
Survival boost for Votrient in mRCC
October 2, 2012Research and Development, Sales and Marketing GSK, Nexavar, Pfizer, Sutent, Votrient
GlaxoSmithKline’s renal cell carcinoma drug Votrient has proved itself non-inferior to a bitter rival, Pfizer’s Sutent, in terms of progression-free …
Government launches Healthwatch England
October 2, 2012Sales and Marketing HealthWatch, NHS, government
The government has launched Healthwatch England, a new statutory body whose role is to ensure the public’s voice is heard …
Merck Serono has redeployed a fifth of axed Swiss staff
October 2, 2012Manufacturing and Production Geneva, Merck Serono
Merck Serono says it has redeployed 260 of 1,250 staff affected by the closure and downsizing of sites in Switzerland …
Lonza wins contract to make gene therapy for heart failure
October 2, 2012Manufacturing and Production Celladon, Lonza, Mydicar
Lonza has been awarded a contract by US firm Celladon for the manufacture of Mydicar, a gene therapy-based drug candidate …
Sigma-Aldrich invest in Scottish site
October 2, 2012Manufacturing and Production Bioreliance, Irvine, Scotland, Sigma-Aldrich
Sigma-Aldrich has announced an expansion of its operations in Scotland with the construction of a powder manufacturing facility at its …
Pharma manufacturing news in brief
October 2, 2012Manufacturing and Production BIA Seperations, Hovione, Lonza, Merck Millipore
Hovione invests in particle design, Lonza signs deal for ADC production plus bioprocess news from BIA Separations and Merck Millipore.
J&J cancer drugs get EU approval
October 2, 2012Sales and Marketing Cancer, Dacogen, EU, J&J, JJ, Velcade
Two of Johnson & Johnson’s key cancer drugs have been shown the green light from the European Commission. Janssen-Cilag International’s …
Cmed Clinical Services Strengthens Management Team
October 1, 2012Research and Development
HORSHAM, UK — September 13, 2012 – Cmed Clinical Services has today announced three new appointments to its management team …
BMS highlights Yervoy survival data
October 1, 2012Research and Development, Sales and Marketing BMS, Roche, Yervoy, Zelboraf
Bristol-Myers Squibb’s melanoma drug Yervoy helps patients survive for longer than if they are receiving standard chemotherapy alone, according to …
Sanofi appoints Paul Chew as chief medical officer
October 1, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Paul Chew, Sanofi
Sanofi has appointed Dr Paul Chew as chief medical officer and head of global medical affairs. Taking up his post …
FDA approves Bayer’s Stivarga
October 1, 2012Research and Development, Sales and Marketing Bayer, FDA, KRAS, Roche, Stivarga, avastin
The FDA has approved Bayer HealthCare’s oncology pill Stivarga to treat patients with metastatic colorectal cancer (mCRC) whose disease has …
Merck gives back vernakalant rights
September 28, 2012Sales and Marketing AF, Cardiome, Merck, vernakalant
Merck has dealt a further blow to Cardiome Pharma Corp by handing back all marketing and development rights for the …
International guide to social media launched by TranslateMedia
September 28, 2012Medical Communications
TranslateMedia, the international translation agency, has created an international guide to social media, to help agencies navigate social media use …
Boehringer’s Engelbert Tjeenk Willink leaves firm
September 28, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Engelbert Tjeenk Willink
Boehringer Board member Engelbert Tjeenk Willink, responsible for Marketing and Sales of Prescription Medicines, has decided to leave at the …
Two hepatitis C drugs win Prix Galien
September 28, 2012Medical Communications, Sales and Marketing Incivo, Janssen, MSD, Victrelis, prix galien
Two new hepatitis C drugs have been given the 2012 UK Prix Galien innovative product award as joint winners in …
Vertex abandons hep C drug
September 27, 2012Research and Development, Sales and Marketing Alios BioPharma, Vertex, hep C
Vertex Pharmaceutical’s pipeline has been dealt a blow with the abandonment of an investigational hepatitis C compound. The US firm, …
CCG warning for doctors from BMA
September 27, 2012Sales and Marketing BMA, CCG, NHS, doctors
GPs have been urged to scrutinise the small print of the new clinical commissioning group (CCG) constitutions before they sign …
GlaxoSmithKline announces Board changes
September 27, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Witty
GlaxoSmithKline has announced several changes to its Board and Committee structure. The GSK Board of directors with effect from 1 …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
